Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...

A 47-year-old man was the first in the world to be treated outside of a study context with a new technique for the symptoms ...

The Michael J. Fox Foundation for Parkinson’s Research has partnered with Grifols, a global healthcare company, to identify ...

Stimulating dopamine-producing brain cells wirelessly with gold nanoparticles has proven effective at treating mice with ...

Neurological conditions are now the leading cause of ill health worldwide, yet remain an enigma. Meet the patients who baffle ...

For the people it affects (and anyone who shares a bed with them) restless legs syndrome (RLS) is a torturous condition.

It can improve motor symptoms, including tremors. Deep brain stimulation (DBS) will continue to see high usage in Parkinson’s ...

NYSE:DHR) Beckman Coulter Introduces Cutting-Edge Research Use Only Assays for Neurodegenerative Disease Research ...

Ketamine disrupts abnormal brain activity, offering long-term relief for Parkinson’s dyskinesia in early clinical trials.

The US Environmental Protection Agency (EPA) has long maintained that the herbicide is safe for use under strict ...